A deal on pharmaceutical production unit project in Uzbekistan was signed on February 23 with the Egyptian company Solyphar, the Pharmaceutical Industry Development Agency said in a statement.
The US $ 20 million project envisages the construction of a production plant of tablets, gelatin capsules and metered powders in Tashkent province.
The annual production capacity will be 500 million tablets, 200 million capsules and 10 million sachets. The production of more than 120 types of drugs is planned.
The unit will reportedly meet the requirements of GMP (Good Manufacturing Practice) and will create more than 200 jobs.